Adalimumab Biosimilar (Wuhan Institute of Biological Products)

The primary objective is to evaluate the human pharmacokinetic (PK) characteristics of a single dose of recombinant fully human anti-human TNF-α monoclonal antibody injection (40 mg/0.8 mL) and adalimumab injection (Humira®) (40 mg/0.8 mL), and to compare the similarity of their pharmacokinetic absorption and metabolic behaviors. The secondary objective is to evaluate the safety and immunogenicity of a single dose of recombinant fully human anti-human TNF-α monoclonal antibody injection (40 mg/0.8 mL) and adalimumab injection (Humira®) (40 mg/0.8 mL), and to compare the similarity of their safety.